Leading Stem Cell Expert: Stem Cells 101 - The Future of Medicine w/ Robert Hariri | EP #147

In this episode, Bob and Peter discuss Stem Cells 101, why it’s not available in America, and the importance of stem cell treatment for humanity. Recorded on Nov 21st, 2024 Views are my own thoughts; not Financial, Medical, or Legal Advice. Dr. Robert Hariri is the Chairman, Founder, and CEO of Celularity, Inc., a leader in human cellular therapeutics developing placental stem cell-based therapies for cancer, autoimmune diseases, and other conditions. A distinguished surgeon, scientist, and entrepreneur, Dr. Hariri is known for discovering pluripotent stem cells from the human placenta and holds over 170 patents in the field. He founded Anthogenesis Corporation, later acquired by Celgene, and co-founded Human Longevity, Inc. Dr. Hariri, an MD and PhD graduate from Cornell University, serves as an Adjunct Professor of Neurosurgery at Weill Cornell Medical College and has earned prestigious honors, including the Pontifical Medal for Innovation and two Thomas Alva Edison Awards. His groundbreaking work continues to shape regenerative medicine and immuno-oncology. He’s also a founding partner of Fountain Life. Learn more about Celularity: https://celularity.com/ Lifebank USA: https://www.lifebankusa.com/ Get my Longevity Guidebook here: https://qr.diamandis.com/book-audiopodcast ____________ I only endorse products and services I personally use. To see what they are, please support this podcast by checking out our sponsors: Get started with Fountain Life and become the CEO of your health: https://fountainlife.com/peter/ AI-powered precision diagnosis you NEED for a healthy gut: https://www.viome.com/peter Get 15% off OneSkin with the code PETER at https://www.oneskin.co/ #oneskinpod _____________ I send weekly emails with the latest insights and trends on today’s and tomorrow’s exponential technologies. Stay ahead of the curve, and sign up now: Tech Blog _____________ Connect With Peter: Twitter Instagram Youtube Moonshots Learn more about your ad choices. Visit megaphone.fm/adchoices

Speaker names marked ? are inferred from speaking time and the show’s known hosts — they are not voice-verified.

• 0:00Peter Diamandis?

  I can go to Panama, to Costa Rica, to Mexico, to Antigua and get stem cells as an American citizen, but I can't get them in the United States. When are they going to be legal here?

• 0:12Speaker 01

  You know, that is a great question that has been plaguing all of us in the industry for decades now. I think the United States is sort of behind the times on this.

• 0:22Peter Diamandis?

  There's been a lot of controversy over the years about stem cells.

• 0:26Speaker 01

  If your baby was born with an extra set of kidneys, an extra set of lungs, an extra heart, would you throw them out at birth? And that's what you actually have when you have a supply of stem cells that can be used in these purposes.

• 0:36Peter Diamandis?

  Let's do a Stem Cell 101, so folks understand why folks are excited about stem cells.

• 0:40Speaker 01

  Just like you renovate your home to keep it in perfect operating condition, it's best to renovate with the original materials that were used to build it in the first place.

• 0:54Peter Diamandis?

  Everybody, welcome to Moonshots. Peter Diamandis here. We're about to have a conversation about a disruptive technology in the longevity and health space. It's called stem cells, and you've probably heard about it, but this is a deep dive in Stem Cells 101 with one of the extraordinary leading figures in the field, Dr. Bob Horry. Bob is the chairman, founder, and CEO of Cellularity. He's an MD, PhD, 170 patents, one of the leading thinkers on using stem cells for autoimmune disease, for fighting cancers, for other conditions. He's an adjunct professor of neurosurgery. He's a co-founder of Fountain Life with me, one of the most extraordinary thinkers on the planet. And he's going to walk you through where they are today, where they're going, why

• 1:39Peter Diamandis?

  you should consider them, what you've heard about them in the past, and why you thought they might not be safe, but what the science and technology shows us for the future. For me, this is a critically important tool in my longevity and therapeutic tool chest. I just finished a book called Longevity Guidebook that talks about how to slow stop, reverse aging, how I've used these technologies to reverse my aging. You can check it out on longevityguidebook.com or in the show. Notes below. All right, let's jump into this incredible conversation with Dr. Bob Hury. Welcome to Moonshots. Hey, buddy. Good to see you. So I have a question for you off the bat.

• 2:20Peter Diamandis?

  I can go to Panama, to Costa Rica, to Mexico, to Antigua. I can even go to Bali, where Genting just created a stem cell facility and get stem cells as an American citizen, but I can't get them in the United States. When are they going to be legal here? When are they going to become available?

• 2:42Speaker 01

  You know, that is a great question that has been plaguing all of us in the industry for decades now. It's really a phenomenon related to the very conservative regulatory nature of the FDA and the systems at work behind testing, validating, and proving the safety and efficacy of therapeutics. And so I personally believe that we've been working with stem cells in one form or another for over 30 years. In fact, bone marrow transplantation is stem cell transplantation.

• 3:19Peter Diamandis?

  Sure.

• 3:19Speaker 01

  This has been around a long time. My personal perspective is that cell therapy, in almost any iteration, in the unengineered form, is intrinsically safe. And so that's why a lot of jurisdictions, very, very active in Asia, you're going to see more activity in Eastern Europe and in the Middle East, they are very receptive to at least providing an abbreviated pathway to approval. Right? And so when you say, are they legal? What you're really asking is, have they been approved by the regulatory community? I think the United States is sort of behind the times on this. And what it needs is it needs a little bit of courage. It needs a little bit of willingness to accept the fact that the value of the therapeutic potential of these things

• 4:01Speaker 01

  outweighs outweighs the potential nominal risk of some uncertainty about long-term safety. We've been doing stem cell treatments in patients for decades and decades and decades. We do not have that long-term safety signal that should concern people. But I do believe that there are other forces behind why there is this very kind of resistant approach to approving and making these products available to patients.

• 4:33Peter Diamandis?

  Yeah, and we'll talk about this because we know so many people who have had significant positive impacts from cellular medicine, from stem cells. And I think of it as one of the fundamentals of the pro-longevity regenerative medicine decade ahead of us. And it's just sad to have to actually, you know, flee the country to go and have access to this tech. And now I'm biased, right? I'm your vice chairman of of cellularity and cellularity is a cellular medicine company, full disclosure. And Bob is, in my mind, the leading figure in this field. He's the first person ever really give me what I would call, you know, massive enthusiasm or even religion on stem cells.

• 5:19Peter Diamandis?

  So I want to get, I want to get into it. I want to do a stem cell 101 for folks to understand what are they? Why are they valuable? Why are folks like flying, you know, in the, in the book behind you, Tony Robbins photo there where you and I co-wrote this. I mean, the opening chapter talks about him having this massive accident and going down for stem cell therapies in in Central America. And instead of going, you know, down the street to do this. So let's do a stem cell 101. So folks understand why folks are excited about stem cells. I mean, you are one of the original pioneers in this area.

• 6:03Peter Diamandis?

  And I want to get into that. But what are stem cells? Why are they important? What's cellular medicine?

• 6:10Speaker 01

  I think everybody understands that at the moment of conception, when sperm and egg come together, a single cell is created that is the first primordial, what we call a totipotent stem cell. And from that single cell, every cell that ever occupies your organs and tissues in your body is derived.

• 6:29Peter Diamandis?

  All forty trillion, all forty trillion cells that make me up.

• 6:33Speaker 01

  Forty trillion cells that are being renewed and recycled over and over and over again in your life. Think about the replication fidelity of taking one cell and making maybe 200 to 300 trillion cells in your lifetime from that single cell. So, think of, that's where the power of stem cells really resides. So let me take a step back and try and explain in a broader way the significance of this biologically. So, we all come from a single cell that is the first stem cell that ever, ever exists with our DNA composition to it. And then those cells divide, and then some of them specialize to become brain cells, hair cells, bone cells, heart cells.

• 7:18Speaker 01

  And that specialization process is called differentiation. What's really cool about stem cells is they reserve the right to specialize or make a copy of themselves. That's what keeps our system capable of going through this constant renovation and renewal process. Now, what's important to keep in mind is, think about the stem cells in every tissue of your body as being your natural repair kit for your body. So, after birth, after, I'm sorry, after conception from that original totipotent stem cell, numerous other versions of these cells, including some cells would take on characteristics of a certain tissue type.

• 8:03Speaker 01

  That's called a tissue lineage. They will actually go to build the final tissue and organ. They'll go to build the heart or the brain. And some of them will remain in stem form. And they sit there in what you and I often call the regenerative engine. That regenerative engine resides there to participate in the renovation process that keeps us healthy and young.

• 8:27Peter Diamandis?

  So let me slow this down a second. That's what you're saying. Okay, we start with one cell. It replicates eventually to form a full embryo. My niece is delivering today, so excited. She has a Life Bank USA kit there to store her placental stem cells. We'll get to that in a little bit. But it becomes that original totypotent stem cell versus pluripotent stem cell, we'll define that in a minute, becomes every tissue type. So it becomes skin, bone, ligament, cartilage, neuron, hepatocyte, lung, everything.

• 9:07Speaker 01

  Yep.

• 9:08Peter Diamandis?

  And so those are when a cell differentiates into a tissue type.

• 9:13Speaker 01

  Correct.

• 9:14Peter Diamandis?

  But within, and you taught me this, within every tissue in our body are these stem cells that can then differentiate into lung, in the lung, into liver, in the liver. You have brain stem cells that can differentiate into brain tissue. You know, you used an amazing analogy that I love and I've used often, and I just wrote about in my longevity guidebook, of the repairman in the mansion. Would you, would you give that analogy again?

• 9:49Speaker 01

  So what I've often said is that, just like you renovate your home to keep it in perfect operating condition, it's best to renovate with the original materials that were used to build it at the first, in the first place. And it's one of the reasons why good contractors will often leave you a supply of tiles and countertops and plumbing supplies and so on, so that as you're going through the process of repairing over the years, you're repairing it back to perfect condition. Nature does that for you by keeping a little supply of stem cells in every organ and tissue of your body. And those stem cells get called upon to do the repair process. It's the natural repair kit. Now, over time,

• 10:32Speaker 01

  you exhaust that supply. And we often think of the aging process, one of the hallmarks of aging, being that you simply use up your stem cell reservoir. And it kind of makes sense, right? Just like you would use up the tiles that are left over for renovating your bathroom, you can use up the stem cells as well. Now, it's important to keep in mind that what makes a stem cell so valuable and useful is its ability to specialize in a versatile way. Meaning that it doesn't necessarily have to be fate-directed. So, stem cells in your liver have the ability to become hepatocytes, actual liver metabolizing cells, but they can also become biliary tract cells.

• 11:15Speaker 01

  They can also become blood vessel cells. They can also become cells that are support cells. And so that, they choose their fate based upon demand. Yes. And that's really critical. We actually know now that a lot of that choice, a lot of that fate choice occurs directed by where the cell is. And so, we know that every tissue in our body is a combination of a structure, a template occupied by cells. That template provides chemical signals that tells the cell where it is. I often say it's like you walk into the mall and you look at the map and it says you are here, and now you're not able to find, you know, Abercrombie and Fitch or whatnot.

• 12:00Speaker 01

  The truth of the matter is, the same thing happens in the body and in our tissues. The different cells, the different stem cells on the tissue know where they are and they specialize in an appropriate way. That's why if I give you, if I inject stem cells into your bloodstream and they get to the liver, but they don't yet become liver cells, they don't eventually make a mistake and become a brain cell. That specialized maturation process is very much orchestrated by the environment.

• 12:31Peter Diamandis?

  Did you see the movie Oppenheimer? If you did, did you know that besides building the atomic bomb at Los Alamos National Labs, that they spent billions on biodefense weapons? The ability to accurately detect viruses and microbes by reading their RNA? Well, a company called Viome exclusively licensed the technology from Los Alamos Labs to build a platform that can measure your microbiome and the RNA in your blood. Now, Viome has a product that I've Personally used for years called Full Body Intelligence, which collects a few drops of your blood, spit and stool, and can tell you so much about your health. They've tested over 700,000 individuals and use their AI models to deliver members

• 13:15Peter Diamandis?

  critical health guidance, like what foods you should eat, what foods you shouldn't eat, as well as your supplements and probiotics, your biological age and other deep health insights. And the results of their recommendations are nothing short of stellar. You know, as reported in the American Journal of Lifestyle Medicine, after just six months of following Viome's recommendations, members reported the following: a 36% reduction in depression, a 40% reduction in anxiety, a 30% reduction in diabetes, and a 48% reduction in IBS. Listen, I've been using Viome for three years. I know that my oral and gut health is one of my highest priorities. Best of all, Viome is affordable, which is part of my mission to democratize health.

• 14:00Peter Diamandis?

  If you want to join me on this journey, go to viome.com/peter. I've asked Naveen Jain, a friend of mine, who's the founder and CEO of Viome, to give my listeners a special discount. You'll find it at viome.com/peter. So I think one thing that's important to discuss here is what happens as you age to your stem cells and I would call, you know, stem cell exhaustion. And again, this is research that you've done and you've brought to the industry here is how many stem cells you begin with as a newborn? And where do you end up at the end of life? And it's like another version of your mansion story is

• 14:44Peter Diamandis?

  imagine you built a giant mansion. I've heard you present this. And in the beginning, your mansion has a whole bunch of repairmen and it has perfect instructions. And as the repairmen are keeping things going, following the instructions, the mansion stays in great shape. But eventually, the repairmen or women start to die off and the population of people being able to repair the mansion begins to degrade and eventually fall away. And the instruction set begins to blur and tatter. Your ability to keep the mansion in good structural health disappears. And you're getting that as well with stem cells. So talk to us about the change in populations.

• 15:30Speaker 01

  So, um, every stem cell has the, I always say, every stem cell retains the fully transcribable genome. What that means is we know that our biological software is, is in our DNA, in our genetic material, and that software is used to make all of the necessary chemicals and proteins and, and signaling molecules that drive the functionality of every cell in our body. And those functions differ based upon the organ or tissue. Liver cells have part of their genome dedicated to liver functions, and in the process of becoming a liver cell, part of the genetic material gets silenced so that it's very efficient in what it does.

• 16:15Speaker 01

  The stem cell, in contrast, retains all that versatility, the ability to read the whole genome. You, you know that when we were, when we first started to build our interest in this field, we created a company called Human Longevity. And Human Longevity was dedicated to reading, interrogating the genome of long-lived people to better understand what might be a hallmark of long life. Well, if you remember, um, our, our, our former partner, Craig Venter, the first scientist to see into the human genome, always spoke about DNA as biological software. And I always spoke of stem cells as the mini-computer.

• 16:53Peter Diamandis?

  Yeah.

• 16:53Speaker 01

  That the software resided in the nucleus, and all of the, all of the reading and writing of that software took place in the cell, the cytoplasm of the cell, and the surface of the cell acted like a keyboard. And so if you think of it in that model, then what a stem cell is that is so valuable to us is it's like a perfect, uncorrupted reboot disk, master boot disk, that as long as you keep it in good condition, anytime your software gets damaged, and your software gets damaged by mutation, it gets damaged by exhaustion, it gets damaged by chemical adulterance, anytime that happens, if you can reinstall the software...

• 17:35Speaker 01

  With this master boot disk, you can get back to a state of of high health, high functionality.

• 17:41Peter Diamandis?

  By the way, anybody under thirty five may not know what a boot disk is, but it was what what you would, what you used to get with your computer that would boot up the computer um and install the

• 17:53Speaker 01

  Yeah.

• 17:54Peter Diamandis?

  Yeah, in the initialization of your of your disk drive. Anyway, but the analogy still still holds. So one of the things you mentioned to me is like between birth and death, you get something like a hundred to a thousandfold reduction in the number of stem cells in each of the tissues of your body. Is that is that true?

• 18:16Speaker 01

  We know that a hallmark of youth is a very abundant, to use a term that's important, an abundant, healthy supply of stem cells. So if you look at one organ system, let's look at bone marrow, okay? And people know bone marrow makes makes the blood, the blood cells, the red blood cells, the white blood cells, the platelets. Bone marrow is filled with stem cells that do all that. At the top, early in life, early after birth, if you were to measure the number of stem cells in the bone marrow of a of a eight week old, about one in twenty to thirty thousand cells in the bone marrow of a newborn is a stem cell.

• 18:58Speaker 01

  Over your lifetime, that number declines, it declines exponentially. So if you look at the bone marrow of an eighty year old, it's one in twenty to thirty million cells.

• 19:07Peter Diamandis?

  Thousandfold reduction.

• 19:08Speaker 01

  Thousandfold reduction. Now, it should be obvious to everybody that the more stem cells you have, the more you're able to respond to the need for repair and renovation. And as you get older, if it's harder to find it, harder to find a stem cell to do that work, you're not going to repair back to the same state of function and health. So think about it as you're using up your your toolkit supplies.

• 19:34Peter Diamandis?

  You know, you've talked about this with the stem cells. Again, I love the term as a regenerative engine of your body and that we have the ability now to just not accept that, right? So people who've heard this conversation on these podcasts with me about longevity know that we are in peak condition typically in our late twenties, like 27 to 30 years old. And it's a slow decline of loss of muscle, a loss of immune function, a loss of hormonal balance, and very significantly, a loss of stem cell capacity. And you can accept that and accept your fate, or you can fight against it. And I think one of the things that that

• 20:18Peter Diamandis?

  you have been leading the charge on, and I remember the first conversation you know, I had about, and I was like, oh, my God, this is incredibly exciting, is the idea of stem cell supplementation and the idea of being able to store, store your own stem cells, we'll get to that, but also to utilize placental stem cells.

• 20:44Speaker 01

  Right.

• 20:45Peter Diamandis?

  So I want to talk about and use those to augment your stem cell populations and even augment your immune system. And so not accepting what is and saying, no, I want to restore my level of regenerative capability in my body. And that is the vision. And I feel confident for what you, the work that you've done and others have done, that it is definitively possible. And we'll get, we'll get to that.

• 21:18Speaker 01

  Well, I got into this field.

• 21:19Peter Diamandis?

  Yeah, that's why you're in the field, right? And I want to talk about how you got into this field. But, but before that, let's talk about the different types and origins of stem cells, because there are lots of different types of stem cells. And let's define them, their utility. When people say they got stem cells, what are the, where might they have got them from? Yeah. So if you don't mind, walk me through that.

• 21:42Speaker 01

  So there's two important concepts you just touched on. One is that

• 21:48Speaker 01

  If we could augment or supplement our reserve of stem cells with a supply of stem cells out there, that's good. That's a good thing, right? We already know it's well accepted in the, in the scientific community that a hallmark of aging is exhausting your stem cell supply. And it makes sense, right? It's intuitively logical to everybody. If, if my body repairs itself by stem cells and I run out of stem cells, I stop repairing myself, right? That is obvious to everybody. The first concept is that if you can supplement or augment your stem cells, that's a good thing. Now, 30 years ago, I said, well, wait

• 22:28Speaker 01

  a second, since I know I can get stem cells from the leftovers of a, of a healthy pregnancy, and it's easy for me to isolate those cells and put them into a state of suspended animation by cryopreserving them, freezing them at ultra-low temperatures. If I need them later in life, can I just thaw them out and use them? And the concept there is true. You can do that. And that's the whole foundation for the newborn cell banking industry, which has been around for over 30 years. The second concept you had-

• 22:58Peter Diamandis?

  Before we, before we go there, can I just mention, you, you mentioned the, the leftovers of pregnancy. So just to be clear about this, for folks to, to get an image here, when, when, and when an embryo is in utero, it is getting a supply of cells from the placenta, right? Which, you know, I use a term, and thank you for crediting me for it, of it's the placenta is a 3D printer that manufactures the baby.

• 23:34Speaker 01

  Right.

• 23:35Peter Diamandis?

  Right? And, and so-

• 23:36Speaker 01

  I love that concept.

• 23:37Peter Diamandis?

  And so the placenta has like all of the stem cells in it, the original boot disc, which is your term I utilize. And so you normally, in labor and delivery room, pay for your expelled placenta to be burned in the incinerator. And you pay a, pay a fee there.

• 24:00Speaker 01

  It's a waste material.

• 24:01Peter Diamandis?

  A waste material. But it's crazy because it's like one of the most powerful materials. It's like throwing away an extra set of organs for your child.

• 24:10Speaker 01

  That's a, it offended me, it offended me to see this beautiful tissue being discarded. And by the way, people say, Bob, why is it, why is a neurosurgeon, you know, chasing placentas? You know, they thought, I thought I lost my mind. The reality is that, um, uh, you know, I recognized that, that this was a pristine tissue. Right? It's the age of the newborn. It has structure, function and cellular content that is about as good as you can, it's going to get. Um, and most importantly, it, these are, these are, as you said, these are just paid to be disposed of when they're readily available. All you needed to do was come up with an industrialized process to utilize those materials and cells.

• 24:55Speaker 01

  So, so to your, to your point, um, the, the placenta is an ideal place to get leftover cells. It all started when we recognized that you could find blood, blood, bone marrow and blood stem cells left over in the circulating blood of the umbilical cord at the time of birth. And, you know, you clamp the cord, you cut the cord, baby in a little piece of cord goes one place, the placenta and the umbilical cord goes into the wastebasket. My concept at the beginning was why let it go into the biohazard wastebasket? Collect it, process it and use the benefits of our, what we know about cryopreserving cells to store them away forever. And so that's that.

• 25:38Peter Diamandis?

  Yeah, I just, I just want, I want to break that down one second because they're, uh, first of all, uh, one of the divisions that, uh, that cellularity has is Life Bank USA. And a lot of folks might've heard of cord blood banking, where you actually take the cord blood, um, which has, uh, hepatocyte stem cells, right?

• 26:01Speaker 01

  Hematoid, hematoid.

• 26:02Peter Diamandis?

  Hematoid steps. Yes, thank you, blood stem cells. And, um, and that has always been the biggest industry, but it's missing the point because what you really want is the stem cells that make up all of the tissues of the body. And, and that's in the placenta. So, uh, so Life Bank USA is someplace where if, if someone listening is having a baby, like my two 13 year old boys now, 13 years ago, we stored their placentas.

• 26:32Peter Diamandis?

  Uh, well, the cells out of the placenta with with you, you have a you have a room full of cryo cryo freezers. And I'm saying, Bob, where are my kids stored? And I go over and say hello to to their stem cells. And now 13 years later, my niece Christina is having her baby today, and they have a Life Bank USA collection kit. Well, they'll collect the placental, the placenta and some cord blood, and that gets shipped to you and then processed. And then her newborn will be on, I think it's a moral obligation for any parent to to save that for their child.

• 27:10Speaker 01

  I couldn't agree with you more. Look, 30 some odd years ago, and I give you I give my older daughter Alex credit for this, right? When I was a young surgeon and she was in utero, and I went down to see the first trimester ultrasound, I tell you this story all the time. And I looked at her little peanut sized embryo, but the placenta was already a big organ. I said to myself, well, wait a second. In medical school, we were taught that the placenta was a vascular connection between the mom and the developing baby. As an engineer, when I looked at that, it didn't make sense to me because because if she was just a peanut size, and the placenta was already a big organ, it suggested to me that the placenta played a role in making that embryo become a fetus and beyond, right?

• 27:55Peter Diamandis?

  Yeah.

• 27:55Speaker 01

  It was participating like a 3D printer in printing the baby. And you said something very important, which is, if you look at an embryo, there just aren't enough cells in an embryo, even at the maximum rate of division, to build a baby in nine months. Some of the additional cells necessary to build that baby have to come from somewhere, and they come from the supply depot, and the supply depot is the placenta.

• 28:19Peter Diamandis?

  Yeah. So I just want people to recognize that the placenta is a valuable, a valuable asset to a family.

• 28:29Speaker 01

  But listen, listen, we're talking to government leaders in certain jurisdictions. This should almost be a medical imperative, because if you have this supply of repair and starting material, you may in fact be able to to to prevent and interrupt.

• 28:47Speaker 01

  Disease progress and and we're in the air we're in the era of gin of cellular engineering. You can fix things if I have your stem cells from your placenta stored. That's the perfect blank canvas to to subject to all these new ways of editing the genome, making you a better, superior, healthy individual, creating immune cells that now target your disease, fixing your immune cells that give you autoimmunity. I mean, all these things are possible if you have the raw material supply. And you and you remember almost 20 years ago, I did that little skunk works experiment where I collected stem cells from the placenta from newborn rats.

• 29:30Peter Diamandis?

  Yep.

• 29:30Speaker 01

  Processed them and stored them and gave those rats back their stem cells as they aged and the animals lived 40% longer than the untreated end, right? So we you and I both know this is a potential cornerstone of the of the technologies that will allow us to live healthier, longer lives.

• 29:48Peter Diamandis?

  Everybody, I want to take a short break from our episode to talk about a company that's very important to me and could actually save your life or the life of someone that you love. Company is called Fountain Life and it's a company I started years ago with Tony Robbins and a group of very talented physicians. You know, most of us don't actually know what's going on inside our body. We're all optimists until that day when you have a pain in your side, you go to the physician in the emergency room and they say, listen, I'm sorry to tell you this, but you have this stage three or four going on. And, you know, it didn't start that morning. It probably was a problem that's been going on for some time, but because we never look, we don't find out.

• 30:31Peter Diamandis?

  So what we built at Fountain Life was the world's most advanced diagnostic centers. We have four across the US today and we're building 20 around the world. These centers give you a full body MRI, a brain, a brain vasculature, an AI enabled coronary CT looking for soft plaque, DEXA scan, a GRAIL blood cancer test, a full executive blood workup. It's the most advanced workup you'll ever receive. 150 gigabytes of data that then go to our AIs and our physicians to find any disease at the very beginning. When it's solvable, you're gonna find out eventually. Might as well find out when you can take action. Fountain Life also has an entire side of therapeutics.

• 31:15Peter Diamandis?

  We look around the world for the most advanced therapeutics that can add 10, 20 healthy years to your life, and we provide them to you at our centers. So if this is of interest to you, please go and check it out. Go to fountainlife.com/peter. When Tony and I wrote our New York Times bestseller, Life Force, we had 30,000 people who reached out to us for Fountain Life memberships. If you go to fountainlife.com/peter, we'll put you to the top of the list. Really, it's something that is, for me, one of the most important things I offer my entire family, the CEOs of my companies, my friends.

• 31:55Peter Diamandis?

  It's a chance to really add decades on to our healthy lifespans. Go to fountainlife.com/peter. It's one of the most important things I can offer to you as one of my listeners. All right, let's go back to our episode. I love this. Okay, so I want people to realize that you can get stem cells from the placenta. Some companies will give you stem cells from the umbilical cord.

• 32:23Speaker 01

  And then the umbilical cord, cord blood, right?

• 32:26Peter Diamandis?

  And cord blood. But there's a few other options for where people get stem cells. Can you run through those?

• 32:32Speaker 01

  Yeah, so in an effort to make stem cells available to people, technologies like induced pluripotency was created. Yamamaka won the Nobel Prize for figuring out how to take one of your mature specialized cells and reprogramming it so it acts like a stem cell. That was because not everybody had their placenta stored at birth or their cells stored early in life. But I'm here to tell you, as phenomenal and exciting as that technology is, It's going through a lot of acrobatics to make an adult cell behave like a placental cell. And even though you might turn on pluripotency, you don't change the age of that cell.

• 33:16Speaker 01

  And there are other parts of the cell besides the parts that get reprogrammed that age, mitochondria age, cell membranes age, et cetera. And so I am here to say the placenta is the ideal alternative, even if you don't have your own cells banked. And that was one of our seminal breakthroughs and discoveries early on, which is that lo and behold, aside from the fact that the placenta is the stem cell factory, the cells in the placenta are nature's universal donor cells. And you've heard me talk about this, Peter.

• 33:48Peter Diamandis?

  Absolutely.

• 33:49Speaker 01

  So I often say, mom and dad contribute 50% each of the DNA of their offspring. So the fetus and its placenta, growing inside mom's womb, is only a 50/50 match to mom. Yet she doesn't reject it and it doesn't reject her. That's pretty cool, right? Well, what about surrogate pregnancy? In surrogate pregnancy, mom's not even related to the placenta or the fetus that is being developed, and she doesn't reject it. So it's proven by nature, and I often say mammalian evolution could not have occurred without the placenta becoming a perfect, universal donor tissue, able to tolerate

• 34:34Speaker 01

  the existence of a different phenotype and different serotype. And so that's the elegance of having the placenta, is I can use those cells in a completely unrelated recipient.

• 34:46Peter Diamandis?

  So there is those, and then let's talk about where, so there's autologous and allogeneic. Can you try to explain those terms?

• 34:56Speaker 01

  Explain those concepts, right? Autologous means the cells come from you.

• 34:59Peter Diamandis?

  Auto self, yeah.

• 35:01Speaker 01

  You can get stem cells from your blood, from your bone marrow, from your adipose tissue. There's lots of places you can get stem cells that are your own. Or you can take a mature cell like a like a fibroblast from your skin. You could subject it to Yamanaka's methodology and you can induce pluripotency. And that's now a stem cell that has the versatile ability to divide, et cetera. So that those are two of the types you can get stem cells from parasites, from the from the not parasites, but perisites, these are the cells that line blood vessels. Okay, you can get stem cells from bone marrow, from peripheral blood that you mobilize the stem cells from bone marrow into.

• 35:46Speaker 01

  And you can get stem cells from virtually any tissue if you're willing to take a scalpel to that tissue.

• 35:52Peter Diamandis?

  Nice.

• 35:52Speaker 01

  In contrast, there's no risk to collecting cells from the placenta. It is it is waste material. The baby is already born and off enjoying its life. When the placenta is expelled, goes into the wastebasket, comes to our laboratories and gets processed. And from one placenta, we can produce tremendous quantities of stem cells.

• 36:16Peter Diamandis?

  And then allogeneic is refers to?

• 36:20Speaker 01

  Allogeneic means the cells come from somebody else. And you in those cases, you have to you have to if they're not derived from an allogeneic placenta, you have to make certain that there's no immunologic conflict between the donor and the recipient.

• 36:37Peter Diamandis?

  Yes.

• 36:37Speaker 01

  Now, allogeneic therapy is really the hallmark of efforts to create off the shelf cell therapy products. Autologous cell therapy products, like for example immunotherapy for cancer, means you got to collect your own cells, process them and then get them back at some point in the future.

• 36:55Peter Diamandis?

  So Bob, there's been a lot of controversy over the years about stem cells, a lot of fear and concerns. Where did that originate from? What what have people heard about that's caused this concern? That you can assuage their fears about?

• 37:13Speaker 01

  Well, you remember from medical school, embryology is the study of how we originate from a single cell into an embryo and then form a fully functioning human being. It was that original work that led to scientists looking at the leftover embryos from in vitro fertilization program, these are the ones that are going to be discarded because they're not used, to see if they could isolate some cells and then grow them up into a population of cells that could potentially be used in therapy. That means you have to destroy an embryo. And early on, the controversy that erupted was that at the stage of when you can isolate

• 37:58Speaker 01

  stem cells, that embryo still has the potential to go on to become a human being. Does it constitute a life that you should not be allowed to compromise or sacrifice? That was the fundamental origins of the controversy. Then, because you can get stem cells from a few stages down in development, from the fetus, and as a byproduct of abortion, scientists show you could isolate stem cells from the leftovers of the abortion process, these put a very, very significant part of the community under great concern that there could be a very perverted incentive to create human

• 38:42Speaker 01

  life in the form of an embryo or a fetus, just to destroy it.

• 38:46Peter Diamandis?

  Yeah.

• 38:47Speaker 01

  And so the pro-life, pro-choice debate was the foundation upon which the controversy around stem cells really emerged. And I'm very happy to say that our discovery of the placenta as an ideal alternative to that. And by the way, the placenta is pro-life and pro-choice.

• 39:12Peter Diamandis?

  Yes.

• 39:13Speaker 01

  So there is no, there is no objection to using the leftovers of a full-term healthy pregnancy to derive stem cells. It's abundantly available, the economics are better, and if I can get a dozen cells from an embryo, I'm lucky. I can get a billion cells easily, multi-billion cells from a placenta. So the sheer, the sheer logistical convenience of using a placenta, all of the characteristics I'm telling you about, the, the immune tolerating ability of the placenta, the universal donor characteristics, all that make the placenta just an ideal source to obviate the need to use for embryos or fetal material.

• 39:52Peter Diamandis?

  Yeah, so I just want folks to understand the original controversy and concerns originated from the idea of using embryonic stem cells from an abortion, from a fetus. And today, the stem cell industry, under Bob's leadership and others, has matured far past that, where we can now identify, we can give you back your own stem cells, we can, we can extract them, we can concentrate them, we can manipulate them a number of ways, we should talk about that, again, because that's not yet FDA-approved, hopefully, under a new administration, it will be.

• 40:32Peter Diamandis?

  Or we can give you placental or umbilical cord stem cells, allogeneic, from somebody else, which are safe and have been done. How many, how many total allogeneic stem cells treatments do you think, your best guess, have been done around the world?

• 40:51Speaker 01

  Oh, millions.

• 40:52Peter Diamandis?

  Millions, okay, so, yeah, so I mean, I just, this is not like a, a wild frontier of an idea someone came up with in their garage and is, is trying on you.

• 41:00Speaker 01

  Exactly. Here's, here's, you know, new, bad news travels fast, okay? If self there, and I make this argument all the time, and, and, and I sometimes pit myself against others in the field. If bad things happen from cell therapy, if bad things happen from using stem cells in treating different diseases, the bad news would travel fast. Now, there have been a few isolated situations where people with irreversible, hopeless diseases sought cell therapy from, let's admit it, from certain unscrupulous opportunistic providers.

• 41:36Peter Diamandis?

  And as a therapy of last resort for them because they're trying everything.

• 41:41Speaker 01

  That's right. And listen, I have such a lot of respect for the FDA. The current head of the division of the FDA that oversees cell therapy, Dr. Peter Marks, has an incredibly complicated, difficult job, and he has done an amazing, amazing job in focusing attention. He wants to see these therapies approved. He wants to make sure they're approved the right way, and he wants to make sure that there's never a shortcut in producing the products. I salute that completely, and I celebrate that completely.

• 42:14Peter Diamandis?

  Yeah, I mean, it's important for people to know there are a lot of mom and pop shops around the country that will promise you stem cell treatments. And you need to really understand the origin, their experience, because they're not legally doing it. Let's begin with that.

• 42:34Speaker 01

  They're operating in the gray zone between a fully developed, regulated therapeutic that meets the high standards of safety and efficacy prescribed by the FDA. They try and go around that. Groups like ours do the hard work of taking these candidate therapies through the process of clinical development, clinical trials, where we are controlling the treatments, we're controlling the analysis, we're controlling the manufacturing, because that's the best way to ensure that no one takes a shortcut to transforming the way a disease is treated. But I'll tell you this much, I do believe that there is room here.

• 43:19Speaker 01

  I do believe there's room here, and I'm in the dialogue. There's room to be more receptive and more open to accelerating the process of review for cell therapies, and also, and this is a little pet peeve of mine, taking advantage of the long safety track record of cell therapy. And allowing some of the evaluation to take place on the run. In other words, have some form of a provisional approval process where cell therapies that meet a high standard for safety, okay?

• 43:54Peter Diamandis?

  Yeah.

• 43:54Speaker 01

  Are allowed to be tried, particularly in some of these hopeless diseases. Let's, let's talk about ALS, right? Lou Gehrig's disease. Nothing works there. You're gonna die if you have ALS. I don't see a downside to using a number of cell therapy products that meet that safety standard and then collecting, rigorously collecting the data. It'll actually do, do us a big favor to open up the number of programs where we're, where we're very rigorous about collecting data in order to make better decisions about what's, what is acceptable or not acceptable to be moved into the therapeutic armamentarium of doctors.

• 44:32Peter Diamandis?

  Let's talk about this social proof here. There have been a number of success stories, right? Again, I mentioned the opening of the Life Force book and where, you know, Tony calls me up and he goes, man, I've just had the worst snowboarding accident and I have just massively injured my shoulder. What should I do? And I say, Tony, you need to talk to Bob Horry. He says, okay. I say, Bob is, you know, for me, my world's expert in stem cells and I think, you know, these types of injuries could benefit. And he called you. And at that time, he, you know, we were both recommending utilizing the Panama Stem Cell Institute.

• 45:17Peter Diamandis?

  I think now we've seen the emergence of down in Costa Rica, RMI, the Regenerative Medicine Institute, under Vince Giambapa. And most everybody that we recommend, who needs this level of allogeneic stem cells, goes down there until we have them operational here in the US, perhaps at Fountain. But take the story from there. And I'd like to hear some other success stories that you could share.

• 45:46Speaker 01

  So Tony is an example, and by the way, you and I fall into the same category. We're at that age where we break stuff, you know, we tear stuff and our body makes a great attempt to mobilize our own stem cell populations and get them to the injury to participate in their repair. But sometimes it's too little, too late. And so in Tony's case, and let's face it, Tony's like a professional athlete times 10, right? Aside from being 6'8" and 260, 270 pounds, you know, in a physical specimen, he taxes his body to the absolute limits, right? I mean, you and I, you and I are blown away when we're with him at his house and he's got, he's got basically a professional gymnasium where he works out like a maniac.

• 46:31Speaker 01

  When he tore up his shoulders, tore up his hips and hurt his back. He either, he either had to go for prosthetic replacement type surgery or, or he had to attempt to turn up the regenerative power of his body. And the only way to do it, because his own cells were either too limited, too little or too late, was to augment it with newborn cells. And we all know, as is covered in the book, he had a life-changing response. I'm, I too, I have had, I have had 30 some odd orthopedic procedures in my life. My shoulders have been torn up. I have no rotator cuffs.

• 47:13Speaker 01

  The only thing that keeps me active is I have range of motion and I can do so is I've used cell therapy and the byproducts of cells to stimulate the repair process and tamp down the inflammation that causes the functional decline.

• 47:27Peter Diamandis?

  Yeah, I'll give a quick aside there for myself. I had, I ran an experiment, not on purpose, but in retrospect, where I had the same surgeon do the exact same surgery on my two shoulders about 10 years apart. And it was a, I had a bone spur and rotator cuff injury and pain where I couldn't sleep. And on one side, my left side originally, that had no regenerative medicine impact. On the right side, after the surgery, I had two injections of Exosomes. And Yeah, I was 10 years older and my recovery time was a fraction.

• 48:12Peter Diamandis?

  And my pain was a fraction of what it was in my other shoulder. Now, listen, this is subjective, but it was like, wow, that was different.

• 48:22Speaker 01

  Yeah, yeah. Listen, me too. I mean, when I tore my, uh, my shoulder up and, um, uh, and I couldn't sleep. The pain was unbearable. I couldn't move it. I, I couldn't load the, uh, the, the bicep. Um, when I went and got first placental cells injected into one shoulder and within a matter of days had considerable reduction in pain and improvement in function. And then when I tore the other one up, I used exosomes just like you did and got very noticeable, quantifiable relief. And most importantly, it, it, it's turned off the processes that would lead to long-term dysfunction like scarring.

• 49:03Peter Diamandis?

  Yes, scarring.

• 49:04Speaker 01

  Like, like changes to bone and cartilage and all that. So, look, we, we're, we're, we're proof in, proof in practice that this stuff actually does work. And, and by the way, people wouldn't be seeking these therapies if they, if there wasn't enough evidence from other people as well as growing evidence in individuals themselves that this stuff actually is an alternative to other forms of therapy.

• 49:31Peter Diamandis?

  You know, Bob, two things. One, first off, can you explain what an exosome is?

• 49:36Speaker 01

  Yep.

• 49:37Peter Diamandis?

  And secondly, um, why haven't the clinical trials been done yet? That allow the FDA to say, yea verily, this is safe and efficacious.

• 49:50Speaker 01

  Well, first of all, let me say this. There have been a lot of clinical trials that I don't necessarily agree with how the data has been analyzed and interpreted. Um, the, I believe the bar for, um, for proving efficacy in self therapies has been unusually high.

• 50:11Speaker 01

  The best example are in the treatment of of heart failure after myocardial infarction. Where, you know, again, once you damage your heart, it's damaged and you don't, you don't, you can't turn it, you can't fix that unless there is a regenerative event that's taking place. So I think the bar has been very, very high. I think we're using, we're using 20th century methodology to evaluate clinical trials in cell therapy. That's a 21st century technology. And so the metrics have to be reevaluated. And I think the time course of looking for changes has to be lengthened. And by the way, you know what the rate limiter for clinical trials is? Money.

• 50:56Speaker 01

  Exactly. It's the time and cost of the trial. And so if you need to have a lens that's looking at the results of cell therapy, that's six months a year, two years down the road, and is also six months a year, two years, and over multiple treatments down the road, it becomes cost prohibitive for the companies who are in this field to do those studies. Listen, there are no big companies doing stem cell clinical development work. They're all developmental stage biotechs. Yeah. Developmental stage biotechs can do only as much as the capital they raise to do those studies. So the, the, the, the, the odds are against,

• 51:38Speaker 01

  you know, getting to the point that you're going to meet those very high regulatory standards. But I do believe, I do believe in partnership with the regulators, we have to say, look, let's, let's agree that no doubt, quality, quality products that are assured to be made under the quality systems of GMP and go through the right kind of release specification testing and so on. With the right kind of evidence of safety, acute and even long-term safety, should be allowed to be introduced into the treatment regimens. Because, by the way, here's the other thing. There's probably a very high likelihood

• 52:22Speaker 01

  that cell therapy in combination with some other elements of conventional therapy is where you get the real return on investment. Okay, the real benefits patients need. We're not doing that because the regulatory system isn't designed to look at things that way.

• 52:38Peter Diamandis?

  Yep.

• 52:39Speaker 01

  But I personally think we're at a stage right now where regulators can be more permissive, allow for real-world evaluation of the long-term benefits of cell therapy in products that meet a high-quality standard and that have the fundamental assurance of safety, acute safety that is necessary to get into the clinic. If we do, we could build the database. And by the way, we live in the world of AI and machine learning. What does AI and machine learning need? It needs big data sets.

• 53:13Peter Diamandis?

  Yep.

• 53:13Speaker 01

  Not 10 patients, not 100 patients, but 10,000 patients.

• 53:17Peter Diamandis?

  So Bobby Kennedy is confirmed. Is he pro-stem cells and pro-regenerative medicine?

• 53:23Speaker 01

  So, you know, I know that there's a great deal of concern. You know, Bobby Kennedy is a very outspoken proponent of looking at therapeutics differently than the conventional views out there. But he is very much a proponent of the US having to advance and innovate in therapeutics, among which cell therapy is one of the categories. And I do believe that he will find a way to work with partners in the FDA and NIH and so on that will be willing be willing to be far more

• 54:05Speaker 01

  Inclusive and receptive to development models where you have a longer lens on the patient's results, that you are looking at a range of different outcome variables, and that you're testing in the context of finding ways for these therapies to fit the conventional treatment regimen. And that may include using with drugs and other components and so on and so forth.

• 54:33Peter Diamandis?

  Real quick, I've been getting the most unusual compliments lately on my skin. Truth is, I use a lotion every morning and every night religiously called OneSkin. It was developed by four PhD women who determined a 10 amino acid sequence that is a senolytic that kills senile cells in your skin. And this literally reverses the age of your skin, and I think it's one of the most incredible products. I use it all the time. If you're interested, check out the show notes. I've asked my team to link to it below. All right, let's get back to the episode. All right, exosomes. Give us a one-on-one on exosomes real quick. People have heard about them. They've heard about them treating for your skin, for your hair, for all kinds of things.

• 55:17Speaker 01

  So, an exosome, think of an exosome as a packet of materials that includes signaling molecules, growth factors, microRNAs, all the ways that cells communicate with each other chemically, gets packaged in what's called an extracellular vesicle. It's a membrane-wrapped little delivery package. And that contains important molecules that can be anti-inflammatory, pro-regenerative, and even help stimulate the expression of certain genes in an individual's genome. And the way they work is that they are released by cells, they can be processed

• 56:00Speaker 01

  and collected in a manufacturing system, and then when administered to an individual, because they're a membrane-bound, they fuse with the membrane of a person's cells and deliver that information into the cell. It's like a special delivery package of an anti-inflammatory growth factor, or a pro-regenerative peptide. That's the way to think about it.

• 56:27Peter Diamandis?

  Okay, so I want to continue. You know, Tony is a great example. You and I have both benefited here. What are some of the other stories that you've been involved in or seen in this in this stem cell success story? Just for folks to have some sense of the broadness here.

• 56:44Speaker 01

  Well, people would be surprised to know that many of our most celebrated

• 56:55Speaker 01

  theater and movie celebrities who are aging but are still facing the demand, the demands of a very active physical life and so on and so forth, have sought out cell therapy in one form or another. Some go to clinics in Europe. Le Prairie, for example, has been a clinic that has been delivering cell therapy. It is not human cell therapy. It's a, it's a, it's cell therapy derived from other species. But they know that the benefits for anti-aging, for preservation of performance, for aesthetic benefits are there. So people have sought it out. I have taken, you know, a number of well-known people to, to different clinical environments

• 57:37Speaker 01

  in, in Central or South America, even in Mexico, Bahamas. And, and these, these folks have, have seen very tangible improvements in a particular need they have. And the most common, I'll tell you right now, the most common thing people go to is for joint problems, right?

• 57:58Peter Diamandis?

  Yeah.

• 57:58Speaker 01

  Arthritis. And, and we're very, very active in advancing these, these approaches to treat something that plagues us all as we age, which is the loss of muscle mass.

• 58:10Peter Diamandis?

  So sarcopenia is one of my... I think, let's talk about that because you've, you've pointed out to me, the Karolinska studies, that muscle mass and longevity are highly correlated. You know, I worked diligently on putting on 10 pounds of muscle mass last year, really through your inspiration and encouragement. So please talk to me about that.

• 58:31Speaker 01

  So people don't recognize how important skeletal muscle is. It's kind of like a forgotten organ. People don't think of it as an organ, right? But muscle makes up 50% of the wet body mass of the average individual, and that means it's the largest synthetic organ in the body. The cells in your muscle make up a whole array of chemicals called the myokinome, and those chemicals influence every cell and tissue in your body, including your brain. And so that's why exercise and getting those muscles working actually is good for your brain health, for your immune health, et cetera. Now, in addition, in addition, muscle is the largest venous capacitance organ, which means it's got the largest network of small blood vessels,

• 59:14Speaker 01

  low-flow blood vessels, low-pressure blood vessels, and that's where a lot of our stem and immune cells take up residence. They sequester there, laying in wait to be, to be, to be called upon to traffic and do their job. Now, I, you, you probably remember 20 years ago, I said that muscle is the, is the forgotten frontier for the therapeutics and pharmaceutical industry. And if you remember, I got very active at finding ways to modulate myostatin, a protein that is designed to, to control how much lean muscle mass you make. And I, I saw that as an opportunity to enhance muscle quality and growth

• 59:56Speaker 01

  with this blockade of this, of this negative peptide. And we actually were able to do that with nutritional products, and there's even a number of pharmaceutical approaches as well. It turns out that this is incredibly important because of the study you just quoted. The Karolinska Institute, which is the Mayo Clinic of Europe, okay? The Karolinska Institute followed 9,000 men for 25 years. And what they found, what they found was that men who maintain healthy lean muscle mass and strength, even if their body mass index was considered to be obese.

• 1:00:35Speaker 01

  Had a higher resistance to dying from cancer or heart disease than any than any other indicator. So muscle mass is a better predictor of longevity and health than body mass index, weight, any of those metabolic markers.

• 1:00:55Peter Diamandis?

  Yeah, I, and I, I love that. The, you know, for me, I keep on saying, any company that will increase muscle mass is a company I want to look at investing in. You know, Bob, you and I are co-founders, along with Tony Robbins and Bob and Bill Cap of Fountain Life. And Fountain Life, you know, has done an amazing job in the diagnostic side, right? We upload about 200 gigabytes of data through full body and brain MRI, DEXA scan, coronary CT, with an AI overlay, low dose lung CT, all the blood biomarkers, your full genomics,

• 1:01:38Peter Diamandis?

  metabolomics, microbiome, a lot. And that's been great. And the goal is, can we answer two questions? Is there anything going on inside you right now you need to know about? And what's likely to happen to you that we can prevent by optimizing you? But that's half of the objective. All right. It's, it's finding disease at the earliest stage when it's most treatable. You and I've always had the vision, we had this back in HLI, but it didn't materialize there. So it's materializing in Fountain, that the diagnostics are important, but the therapeutics are as important. So how do we deliver our Fountain Life members

• 1:02:22Peter Diamandis?

  the highest reward, lowest risk therapeutics? And really search the world for those and then deliver them at the centers. So I want to talk a little about that. I want to get your, your thoughts, because I think we're just at the brink of a lot of these very exciting longevity therapeutics. I mean, that's the goal is to restore function. And you've taught me, it's, you know, are you thinking clearly? Are you looking good? Are you moving well? Right? That's, that's what people want through their, through their 99th birthday.

• 1:02:59Peter Diamandis?

  And so, you know, the question is, you know, are we going to be able to, you know, deliver some of these therapeutic stem cells, exosomes, and other things through Fountain Life? What's your, what's your vision there?

• 1:03:14Speaker 01

  Well, listen, you and I have talked for a long time about what's, what's meaningful. The concept of anti-aging and longevity has been a bit perverted over the years, right? It was seen, seemed to be kind of the, the folly of the wealthy and, you know, not necessarily, you know, there weren't, in some cases, morally justifiable reasons for wanting to live to 150 and so on and so forth. When I was a kid, there was a TV show called The Immortal, and I used to love that show. You might remember it.

• 1:03:43Peter Diamandis?

  Yeah.

• 1:03:44Speaker 01

  He had blood, he had blood to live forever, and so he was hunted by the billionaires who wanted to, you know, take his blood, et cetera. So, look, here, here's the bottom line.

• 1:03:53Peter Diamandis?

  Sure.

• 1:03:55Speaker 01

  Meaningful, long life requires preservation of performance. And I always say it's about high-performance mobility, like you said, high-performance cognition, you got to think, high-performance immunity, and youthful aesthetics. Those four things, in my mind, constitute meaningful, long life. Those are all achievable using many different approaches: nutrition, exercise, et cetera, maintaining muscle mass. But it is the perfect target for the regenerative therapies available through cellular medicine. And when you and I first built Human Longevity, and we went, and then we decided that we were going to now perfect it in Fountain Life,

• 1:04:40Speaker 01

  our objective was to do two things. We wanted to use a proactive approach in healthcare. Like you said.

• 1:04:48Peter Diamandis?

  Yeah.

• 1:04:49Speaker 01

  Identify and eradicate causes of premature death. That's the obvious, low-hanging fruit. You know and I know, life expectancy is an average lifespan of everybody, which means that if it's 80, if it's 78 or 80 years of age... And we know people lived to ninety-five, a hundred, et cetera. A lot of people are dying early. So, step number one, eradicate causes of premature death. What are the causes of premature death that get away from us? They're cardiovascular, they're cancer. Okay, the cardiovascular ones are the explosive things like aneurysmal ruptures, right? Like cardiovascular failure due to electrical issues that cause sudden cardiac death.

• 1:05:34Speaker 01

  Undiagnosed cancers that before you know it, and when you first find out you have them, they're so advanced, they can't be managed. So, anything that can identify stuff early enough to be intervened with, that's a principal target of Fountain Life. And we've already proven it works, right? We know it works.

• 1:05:53Peter Diamandis?

  We've saved hundreds and hundreds of lives.

• 1:05:54Speaker 01

  Hundreds of lives. And we're saving lives in the first community who are making access to this, which are the informed, educated, affluent people who are already getting the best healthcare. Look, how many people do you and I both know, people we know, who have religiously pursued healthcare with the best physicians? And they have a clean bill of health, they come into Fountain Life and we identify a...

• 1:06:18Peter Diamandis?

  Yeah, I mean, Sam Nazarian, who's made this public, who's one of our new partners, building out centers around the world.

• 1:06:27Peter Diamandis?

  I, you know, said, "Listen, Sam, come down and see the Fountain Life facility." I was taking him through to meet Richard Branson at Necker Island, and we stopped through and he went through an upload, he and his wife. And this is a guy who has, has built the greatest hotels in the world. He is, you know, I don't know how close he is or how much of a billionaire or multi-billionaire he is, but best physicians. And he comes through, and at the end of this upload, we find two brain aneurysms. And he's in surgery a week later and he's cured now, but those were ticking time bombs. And it's like, really?

• 1:07:11Peter Diamandis?

  It's like your other doctors didn't find these that have been around for so long? That's insane.

• 1:07:15Speaker 01

  Yeah.

• 1:07:16Peter Diamandis?

  Yeah.

• 1:07:16Speaker 01

  I mean, look, the truth of the matter is, we now have at our disposal, high resolution imaging technology, which the cost has come down with, with the advent of AI and so on and so forth, the ability to interpret is going to improve. And aneurysms are relatively easy to spot as long as you have the imaging study.

• 1:07:36Peter Diamandis?

  Yeah.

• 1:07:36Speaker 01

  And so if for, for a relatively modest amount of money, you can, and you can ensure yourself that you don't have one of these ticking time bombs, it's worth it, right? Likewise, if, if, if the same imaging study can tell you whether or not you have a, a smoldering malignancy in your thyroid or in your, or in your kidney, you know.

• 1:07:58Peter Diamandis?

  Your pancreas, your brain, yeah.

• 1:08:00Speaker 01

  How many, how many of our friends were in perfect health, living the dream? And we, they found out that they had a, a, a subclinical kidney cancer, which, which fortunately is easily addressed when you catch things early. By the way, this is not new. The American Cancer Society said 30, 40 years ago, early detection is the key to survival in cancer, right?

• 1:08:23Peter Diamandis?

  Yeah.

• 1:08:23Speaker 01

  So the faster you find something, the more options you have to treat it. And excisional procedures for cancer, we know are life, lifesaving.

• 1:08:32Peter Diamandis?

  Yeah.

• 1:08:32Speaker 01

  And so just what Fountain Life does in identifying and eradicating these premature causes of death is, is enormous. But more importantly, more importantly, and this is our aviation background is coming out. What if I said to you for 25, since we've known each other, I said, the reason we fly airplanes that can be 20 years old is because we go through a process that, that was developed by engineers. And that's why I like, like, you know, having that engineering background where because of root cause analysis, we figure out what is the source of a mission critical failure? And if it's a mechanical component, you inspect and replace.

• 1:09:11Speaker 01

  At 50% lifespan, so that you never have a mission critical failure. And you learn over time what those are. We already know what the mission critical failures are in biology.

• 1:09:23Peter Diamandis?

  Yeah.

• 1:09:24Speaker 01

  We can, we can, we can use the same proactive approach. And we can, I believe, prevent the tremendous cost of care. Look, we identify a kidney cancer in somebody pre-clinically and treat them. You have saved, you have saved potentially millions of dollars in care that they have.

• 1:09:45Peter Diamandis?

  Yeah.

• 1:09:46Speaker 01

  Right?

• 1:09:46Peter Diamandis?

  You know.

• 1:09:46Speaker 01

  Despite the misery.

• 1:09:47Peter Diamandis?

  It needs to be said as well, um, you know, we have a couple of friends in Dean Kamen and Martine Rothblatt, um, who are doing something extraordinarily magical. And you've spoken about this and you did a lot of the early work as well, which is regrowing organs or remanufacturing organs, right? Going from a stem cell, um, or even going from a skin cell to a pluripotent stem cell with the yamanaka factors, growing up billions of those cells, differentiating them uh, into heart, liver, lung, kidney, and, and remanufacturing a brand new organ with your own DNA, your own certain

• 1:10:25Peter Diamandis?

  surface antigens. It's like, it's the reason that airplanes and, and Ford Model Ts 100 years ago are still operating today is you can replace the parts.

• 1:10:33Speaker 01

  I often, I often tell families who are thinking about banking their kids' stem cells at birth. I said, look, if your baby was born with an extra set of kidneys, extra set of lungs, and an extra heart, would you throw them out at birth? And that's what you actually have when you have a supply of stem cells that can be used in these purposes. And by the way, Peter, you know, I was the first guy to actually take an organ.

• 1:10:54Peter Diamandis?

  Yeah. Tell this story, buddy. I love it.

• 1:10:55Speaker 01

  So, over 20 years ago, um, I was the first guy to take a solid organ and remove all the living cells from the.

• 1:11:05Peter Diamandis?

  What, what organ did you choose?

• 1:11:06Speaker 01

  Uh, we originally started with the placenta. We did with, we did it with the hearts as well.

• 1:11:11Peter Diamandis?

  Yeah.

• 1:11:11Speaker 01

  Basically, wash out all of the cells, the living cells in that organ. Leave behind a beautiful three-dimensional architecture template of the organ. And then inject-

• 1:11:24Peter Diamandis?

  Can I, can I, can I, can I, one second, just to give people a visual here. If you have a heart and you use a detergent, right? This is a detergent. It actually will desegularize the heart. In other words, the cells are falling away.

• 1:11:39Speaker 01

  Right.

• 1:11:40Peter Diamandis?

  But what's left is, and it's hard to imagine this, but there is a, a, a, a massive structure, it's collagen structure, right?

• 1:11:53Speaker 01

  It's a combination of different structural proteins, but it is basically the architecture of the organ.

• 1:11:58Peter Diamandis?

  So it looks like a ghost organ there. That is-

• 1:12:01Speaker 01

  It's translucent, they're beautiful. They look like, they look like a, like a glass cast of the, of the actual organ. And it has all the blood vessels, structures in place. It has all the mechanical structures, the valves and so on and so forth. But you know, when I first did this with a placenta, I basically washed out all of the cells of the placenta and then I could repopulate the organ any, any way I wanted to, based on the stem cells I, I, I implanted into it. So my original invention, my original patent, which was entitled, "The Renovation and Repopulation of Cadaveric Organs and Tissue Matrixes with Stem Cells", was the roadmap for what's being done now by Martine and Dean, where they're basically

• 1:12:42Speaker 01

  using that, that approach to create a repopulatable template and then using cells that are either fate-driven cells from iPSCs or, or their donor cells. And here's the really cool thing. If you inject pluripotent, versatile stem cells into a perfectly preserved matrix of a tissue- They actually know where they are and they differentiate appropriate.

• 1:13:10Peter Diamandis?

  GPS locations.

• 1:13:11Speaker 01

  GPS.

• 1:13:12Peter Diamandis?

  Yeah, amazing. Buddy, I want to wrap with just a quick conversation about Cellularity. And people who look up your bio and you are one of the most brilliant scientist, entrepreneur, engineers that I know and I love you as an older brother. I'm always, I'm always thankful that the fact that you're a couple of years older than me so that, you know, you're the one that's going to be pushing harder than I am on the regenerative medicine side. But, uh, so you used to run the cellular medicine division at Celgene. Uh, which was, how big was Celgene? A hundred billion, a hundred and something billion?

• 1:13:52Speaker 01

  Yeah, we, we grew to a hundred and twenty billion dollar market cap at our peak and Celgene was a remarkable place. The, the best people, I gotta tell you, I, I was blessed to, to be part of that organization. The best leadership, science-driven and courageous. Um, and, uh, you know, uh, it was a great environment to, to, to be, um, risk-taking, risk-tolerant and innovative.

• 1:14:18Peter Diamandis?

  Yeah. Well, so at one point, I remember our conversations, uh, and we said, listen, it's, it's great environment, but you would thrive better if we could spin out the cellular medicine division. And that became Cellularity and folks, it's, uh, can look it up. It's now a public company, CE L U. And you built an extraordinary manufacturing facility that you're in the midst of right now in New Jersey. But it's, it's worth taking a moment to say, when you harvest a placenta, and I do want to put in the show notes here,

• 1:14:57Peter Diamandis?

  folks can go to lifebankusa.com, uh, cause again, I'm just shouting this from the, uh, from the mount tops as I was, as we're recording this, this podcast, I got a text from, uh, my, my sister and my mom. That Christina has delivered, so her daughter's

• 1:15:15Speaker 01

  Congratulations.

• 1:15:16Peter Diamandis?

  You know, welcome to Planet Earth.

• 1:15:19Speaker 01

  I'm gonna let the lab know that the placenta will be here shortly.

• 1:15:22Peter Diamandis?

  Yes, and so, and her, the placenta, her placenta and her child's placenta will be there. And you'll, what do you do with the placenta once you get in? What are the products that you create? Take a second to speak about that.

• 1:15:35Speaker 01

  So, the placenta is procured under very rigorous controls, transported under controlled logistics. And then in our laboratories, it is processed to separate the cellular side of the organ from the tissue side of the organ. And from the tissue side of the organ, we make a whole range of surgical appliances. These are, these are products that are used in wound healing, orthopedics, ophthalmology. And they are basically using the natural architecture of the placental tissue itself to come up with replacements for skin, ligament, tendon, cartilage, et cetera.

• 1:16:16Speaker 01

  And they are increasingly popular as the basis for treating diabetic foot ulcers, venous stasis ulcers, burns, et cetera. The cells go on to be used to produce immune cells, pluripotent stem cells, and a whole range of other products. And people can go to our website, celularity.com, C E L U L A R I T Y dot com, and see all these programs and products. But the bottom line is, is that we're a leading company in cellular and regenerative medicine. And we are perfectly poised to deploy all these therapies in the future of longevity therapeutics.

• 1:16:58Peter Diamandis?

  Amazing, amazing. Bob, I am grateful for you in my life. Thank you for the work that you're doing. And you've been an incredible scientist, CEO, engineer, and brother for me. I hope folks will check out what Cellularity is doing, what Fountain Life is doing.

• 1:17:22Peter Diamandis?

  Start to understand the power that stem cells have and that it is part of our regenerative toolkit, it is part of our future. And it's, you know, we hear about the idea of adding decades of health to our life. This is health span extension, right? And we hear of epigenic reprogramming. But the other big area is cellular medicine, stem cells. We haven't talked about really supplementing your immune system with NK cells and T cells and so forth. We'll leave that to another episode. But love you, brother, and thank you always for our time together.

• 1:18:01Speaker 01

  Peter, I love you. Thanks so much for having me. And you're the inspiration that has gotten us here. So keep it up, man.

• 1:18:08Peter Diamandis?

  Thank you, pal.

• 1:18:09Speaker 01

  See you soon.

• 1:18:10Peter Diamandis?

  See you soon.